share_log

Recursion Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.5%)

Recursion Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.5%)

Recursion Pharmaceuticals | SC 13G/A：超過5%持股股東披露文件(修正)-BlackRock, Inc.(7.5%)
美股SEC公告 ·  10/22 15:30

Moomoo AI 已提取核心訊息

BlackRock, Inc., a global investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on October 22, 2024, indicating a 7.5% ownership stake in Recursion Pharmaceuticals, Inc. This filing, which is an update to previous disclosures, shows that BlackRock now beneficially owns 20,742,797 shares of Class A Common Stock in Recursion Pharmaceuticals. The filing was made under Rule 13d-1(b), which is typically used by passive investors not seeking to change or influence the control of the company. Recursion Pharmaceuticals, headquartered in Salt Lake City, Utah, is the issuer of the securities in question. The filing also includes a list of subsidiaries under BlackRock, Inc. that own 5% or greater of the outstanding shares of the security class being reported.
BlackRock, Inc., a global investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on October 22, 2024, indicating a 7.5% ownership stake in Recursion Pharmaceuticals, Inc. This filing, which is an update to previous disclosures, shows that BlackRock now beneficially owns 20,742,797 shares of Class A Common Stock in Recursion Pharmaceuticals. The filing was made under Rule 13d-1(b), which is typically used by passive investors not seeking to change or influence the control of the company. Recursion Pharmaceuticals, headquartered in Salt Lake City, Utah, is the issuer of the securities in question. The filing also includes a list of subsidiaries under BlackRock, Inc. that own 5% or greater of the outstanding shares of the security class being reported.
貝萊德股份有限公司，總部位於特拉華州的全球投資管理公司，於2024年10月22日向證券交易委員會提交了修訂後的13G表格，顯示其在Recursion Pharmaceuticals, Inc.擁有7.5%的所有權份額。這份申報文件是對之前披露的更新，顯示貝萊德現在有益地擁有Recursion Pharmaceuticals的20,742,797股A類普通股。該申報是根據規則13d-1(b)提交的，通常由 passsive 投資者使用，不尋求改變或影響公司的控制權。總部位於猶他州鹽湖城的Recursion Pharmaceuticals是相關證券的發行者。該申報還包括一份貝萊德股份有限公司子公司名單，這些子公司持有正在報告的安防-半導體類的5%或更多的優先股。
貝萊德股份有限公司，總部位於特拉華州的全球投資管理公司，於2024年10月22日向證券交易委員會提交了修訂後的13G表格，顯示其在Recursion Pharmaceuticals, Inc.擁有7.5%的所有權份額。這份申報文件是對之前披露的更新，顯示貝萊德現在有益地擁有Recursion Pharmaceuticals的20,742,797股A類普通股。該申報是根據規則13d-1(b)提交的，通常由 passsive 投資者使用，不尋求改變或影響公司的控制權。總部位於猶他州鹽湖城的Recursion Pharmaceuticals是相關證券的發行者。該申報還包括一份貝萊德股份有限公司子公司名單，這些子公司持有正在報告的安防-半導體類的5%或更多的優先股。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間